Chinese burdens and trends of diabetic retinopathy 1990-2021 and 15 years forecast: results from the Global Burden of Disease Study 2021

1990-2021年中国糖尿病视网膜病变负担及趋势及15年预测:2021年全球疾病负担研究结果

阅读:2

Abstract

OBJECTIVES: To assess the Chinese burden of diabetic retinopathy (DR) between 1990 and 2021, considering variations by year, age, and gender, as well as to forecast the trends over the next 15 years. METHODS: We evaluated the burden of DR in China based on data from the GBD 2021, examining prevalence, years lived with disability (YLDs), age-standardized YLDs rates (ASYR), and age-standardized prevalence rates (ASPR) over the period 1990 to 2021. Furthermore, we utilized joinpoint analysis and the Bayesian age-period-cohort model to explore the epidemiological patterns of the disease and forecast its impact for the years 2022 to 2036. RESULTS: In 2021, the number of YLDs and prevalence attributed to DR were 86,317 (95% UI: 56,595 to 125,565) and 1.37 million (95% UI: 1.04 to 1.78), respectively. Over the period 1990 to 2021, the AAPC of ASYR and ASPR for DR rose by 0.71 (95% CI: 0.28, 1.14) and 0.43 (95% CI: 0.20, 0.66) in China. Older adults and women experienced a greater burden. Aging and demographic changes are key risk factors for DR, and future trends suggest a decrease in ASYR and ASPR. CONCLUSION: The Chinese burden of DR has increased during the years 1990 to 2021. Despite the anticipated decline in the burden of DR between 2022 and 2036, the importance of bolstering efforts in DR prevention and control should not be underestimated.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。